Page last updated: 2024-08-21

azomycin and Tuberculosis, Pulmonary

azomycin has been researched along with Tuberculosis, Pulmonary in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.56)	18.2507
2000's	11 (17.19)	29.6817
2010's	39 (60.94)	24.3611
2020's	13 (20.31)	2.80

Authors

Authors	Studies
Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y	1
Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R	1
Lyons, MA	3
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C	1
Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V	1
Furin, J; McKenna, L	1
Kudoh, S; Kurashima, A; Ogata, H; Ohta, K; Okumura, M; Yoshimori, K; Yoshiyama, T	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH	1
Jeon, D; Jo, KW; Kang, H; Shim, TS; Yim, JJ	1
Gibiansky, E; Mallikaarjun, S; Wang, X	1
Chopra, S; Dasgupta, A; Thakare, R	1
Chopra, V; Gupta, A	1
Castel, S; Dawson, R; Dooley, KE; Ignatius, EH; Joubert, A; Kellermann, T; Malo, A; Norman, J; Wiesner, L	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Akkerman, O; Alffenaar, JW; Amale, R; Centis, R; D'Ambrosio, L; Ganatra, S; Maryandyshev, A; Migliori, GB; Mullerpattan, J; Pontali, E; Sadutshang, TD; Sotgiu, G; Tiberi, S; Topgyal, S; Udwadia, ZF	1
Li, DG; Ren, ZX	1
Dowdy, D; Merritt, MW; Taylor, H; von Delft, A; Zwerling, A	1
Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Spanevello, A; Visca, D	1
Ade, S; Alikhanova, N; Benedetti, G; Cox, H; Daniels, J; De Azevedo, V; Edwards, J; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Mohr, E; Reuter, A; Shroufi, A; Steele, SJ; Trivino Duran, L	1
Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C	1
Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ	1
Arora, VK; Chopra, KK	1
Dawson, R; Diacon, A	1
Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML	1
Arena, A; Arrieta, F; Bloomer, WD; Papadopoulou, MV; Rebolledo, JC; Rosenzweig, HS; Smith, DK	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Lynch, JB; Szumowski, JD	1
Mayor, S	1
Migliori, GB; Sotgiu, G	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Bhatnagar, R; Bhuyan, S; Das, B; Garhyan, J; Kalita, D; Pulu, I	1
Bianchini, S; Blasi, F; Esposito, S	1
Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T	1
Dawson, A; Silva, DS; Upshur, RE	1
Fujiwara, M; Geiter, L; Kawasaki, M; Kreiswirth, BN; Kurepina, N; Liu, Y; Matsumoto, M; Shashkina, E; Stinson, K; Timm, J; Venter, A	1
Dass, R; Hettle, R; Wirth, D	1
Mancera, RL; Rivers, EC	1
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K	1
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL	1
Lienhardt, C; Raviglione, MC; Vernon, A	1
Dawson, R; Diacon, AH; Donald, PR; Ginsberg, AM; Hanekom, M; Laurenzi, MW; Maritz, SJ; Narunsky, K; Rouse, DJ; Spigelman, MK; van Niekerk, C; Venter, A; Whitney, K	1
Nuermberger, EL; Spigelman, MK; Yew, WW	1
Bifani, P; Dartois, V; Heng, Y; Hervé, M; Kiass, M; Mathys, V; Seah, PG; Siew, JY; Singhal, A; Tay, HC	1
Dawson, R; Diacon, AH; Donald, PR; Geiter, LJ; Hanekom, M; Hittel, N; Narunsky, K; Paccaly, AJ; Venter, A; Wells, CD	1
Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y	2
Boshoff, H; Mukherjee, T	1
Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Barry, CE; Boshoff, HI; Dowd, CS	1
Bishai, W; Grosset, J; Lounis, N; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, K; Yoshimatsu, T	1
Driscoll, DK; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Reynolds, RC; Rose, JD; Tompkins, NM	1
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN	1
Aly, S; Bange, FC; Brandau, S; Ehlers, S; Keller, C; Malm, S; Malzan, A; Wagner, K	1
Zhang, Y	1
Kobayashi, K; Okada, M	1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN	1
Allen, SS; Barry, CE; Carrillo, J; Cho, SN; Eum, SY; Flynn, JL; Gonzales, J; Klein, E; Lee, EG; Lin, PL; Manjunatha, U; McMurray, DN; Park, SK; Raleigh, JA; Ray, SM; Taylor, K; Via, LE	1
Ashtekar, DR; Bhatt, AD; Costa-Perira, R; Nagrajan, K; Rittel, W; Vishvanathan, N	1

Reviews

12 review(s) available for azomycin and Tuberculosis, Pulmonary

Article	Year
Evolution of newer regimens in TB from RNTCP to NTEP. The Indian journal of tuberculosis, 2020, Volume: 67, Issue:4S Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary	2020
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management. Current opinion in pulmonary medicine, 2018, Volume: 24, Issue:3 Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2018
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2013
Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:2 Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug design, development and therapy, 2015, Volume: 9 Topics: Animals; Antitubercular Agents; Drug Interactions; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Long QT Syndrome; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Risk Assessment; Risk Factors; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Bedaquiline and delamanid in tuberculosis. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:15 Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Interactions; Drug Resistance, Bacterial; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
New anti-tuberculosis drugs with novel mechanisms of action. Current medicinal chemistry, 2008, Volume: 15, Issue:19 Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary	2008
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current opinion in pulmonary medicine, 2010, Volume: 16, Issue:3 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Drug Therapy, Combination; Female; Fluoroquinolones; Forecasting; Humans; Male; Nitroimidazoles; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2010
Current development and future prospects in chemotherapy of tuberculosis. Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:5 Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary	2010
Nitroimidazoles for the treatment of TB: past, present and future. Future medicinal chemistry, 2011, Volume: 3, Issue:11 Topics: Animals; Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Discovery; Drug Evaluation, Preclinical; Humans; Molecular Structure; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis, Pulmonary	2011
Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Current pharmaceutical design, 2004, Volume: 10, Issue:26 Topics: Animals; Antibiotics, Antitubercular; Drug Evaluation, Preclinical; Humans; Nitroimidazoles; Randomized Controlled Trials as Topic; Single-Blind Method; Tuberculosis, Pulmonary	2004
Advances in the treatment of tuberculosis. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2007

Trials

12 trial(s) available for azomycin and Tuberculosis, Pulmonary

Article	Year
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study BMJ open, 2022, 08-29, Volume: 12, Issue:8 Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2023
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2020
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:3 Topics: Adult; Antitubercular Agents; Colony-Forming Units Assay; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Nitroimidazoles; Safety; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2021
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:3 Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m Trials, 2019, Jan-16, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2019
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:6 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary	2016
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8 Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Culture Media; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2010
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:7 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2011
Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012

Other Studies

40 other study(ies) available for azomycin and Tuberculosis, Pulmonary

Article	Year
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-15, Volume: 72 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide. Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations. Respiratory investigation, 2020, Volume: 58, Issue:2 Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple; Female; Humans; Japan; Male; Middle Aged; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Pulmonary	2020
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respiratory medicine, 2020, Volume: 167 Topics: Age Factors; Aged; Body Mass Index; Diarylquinolines; Drug Resistance, Bacterial; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nitroimidazoles; Oxazoles; Republic of Korea; Retrospective Studies; Risk Factors; Safety; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2020
Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy, 2020, 12-16, Volume: 65, Issue:1 Topics: Adolescent; Adult; Antitubercular Agents; Humans; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2020
Pretomanid for the treatment of pulmonary tuberculosis. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:10 Topics: Adult; Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2020
A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients. Journal of pharmaceutical and biomedical analysis, 2021, Feb-20, Volume: 195 Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Nitroimidazoles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tuberculosis, Pulmonary	2021
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerging infectious diseases, 2017, Volume: 23, Issue:10 Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary; Young Adult	2017
Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Aug-07, Volume: 50, Issue:9 Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cordyceps; Disease Models, Animal; Flow Cytometry; Immunomodulation; Interleukin-10; Male; Mice; Mice, Inbred CBA; Mycobacterium tuberculosis; Nitroimidazoles; Real-Time Polymerase Chain Reaction; Tuberculosis, Pulmonary	2017
Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 11-01, Volume: 21, Issue:11 Topics: Antitubercular Agents; Cost-Benefit Analysis; Decision Trees; Diarylquinolines; Humans; Models, Theoretical; Nitroimidazoles; Oxazoles; Social Justice; Social Stigma; South Africa; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2017
Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Male; Middle Aged; Models, Theoretical; Monte Carlo Method; Nitroimidazoles; Tuberculosis, Pulmonary; Young Adult	2018
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. The European respiratory journal, 2018, Volume: 51, Issue:6 Topics: Adult; Antitubercular Agents; Female; Humans; Logistic Models; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2018
Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis. Prescrire international, 2017, Volume: 26, Issue:181 Topics: Antitubercular Agents; Electrocardiography; Humans; Long QT Syndrome; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2017
Journey of tuberculosis control in India. The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1 Topics: Antitubercular Agents; Diarylquinolines; Directly Observed Therapy; Goals; History, 20th Century; History, 21st Century; Humans; India; National Health Programs; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8 Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2013
Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11 Topics: Amides; Animals; Antitubercular Agents; Cell Line; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Imidazoles; Isoniazid; Macrophages; Mice; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Sulfonamides; Tuberculosis, Pulmonary	2014
New drug combination may shorten tuberculosis treatment, study says. BMJ (Clinical research ed.), 2015, Mar-18, Volume: 350 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy. The American journal of pathology, 2015, Volume: 185, Issue:7 Topics: Adapalene; Animals; Antitubercular Agents; Bone Marrow Cells; Cell Hypoxia; Down-Regulation; Female; Green Fluorescent Proteins; Humans; Isoniazid; Lung; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Radiation-Sensitizing Agents; Specific Pathogen-Free Organisms; Tuberculosis, Pulmonary; Up-Regulation	2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2016
Reciprocity and Ethical Tuberculosis Treatment and Control. Journal of bioethical inquiry, 2016, Volume: 13, Issue:1 Topics: Antitubercular Agents; Beneficence; Communicable Disease Control; Congresses as Topic; Diarylquinolines; Directly Observed Therapy; Ethical Analysis; Ethical Theory; Global Health; Humans; Moral Obligations; Nitroimidazoles; Oxazoles; Patient Isolation; Personal Autonomy; Pharmacovigilance; Poverty; Public Health; Social Justice; Social Responsibility; Tuberculosis, Laryngeal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Virtues	2016
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC health services research, 2017, 03-08, Volume: 17, Issue:1 Topics: Adult; Antitubercular Agents; Clinical Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Female; Germany; Humans; Linezolid; Male; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Quality-Adjusted Life Years; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2017
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary	2008
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2010
Mycobacterium tuberculosis infection induces hypoxic lung lesions in the rat. Tuberculosis (Edinburgh, Scotland), 2011, Volume: 91, Issue:4 Topics: Animals; Disease Models, Animal; Female; Granuloma; Hypoxia; Immunohistochemistry; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Rats; Tuberculosis, Pulmonary	2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2011, Oct-13, Volume: 54, Issue:19 Topics: Acute Disease; Animals; Antitubercular Agents; Chronic Disease; Ethers; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary	2011
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2011
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Acute Disease; Amides; Animals; Antitubercular Agents; Biological Availability; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Chronic Disease; Dogs; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Rats; Solubility; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary; Urea	2012
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Random Allocation; Tuberculosis, Pulmonary	2005
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Specific Pathogen-Free Organisms; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2005
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary	2006
Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. The Journal of pathology, 2006, Volume: 210, Issue:3 Topics: Animals; Biomarkers; Disease Models, Animal; Electrodes; Female; Granuloma; Hypoxia; Immunohistochemistry; Lung; Mice; Mice, Inbred C57BL; Mutation; Mycobacterium tuberculosis; Necrosis; Nitrates; Nitroimidazoles; Oxygen; Time Factors; Tuberculosis, Pulmonary	2006
[Recent progress in mycobacteriology]. Kekkaku : [Tuberculosis], 2007, Volume: 82, Issue:10 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Bacteriology; DNA-Binding Proteins; Drug Design; Humans; Immunoenzyme Techniques; Japan; Mice; Minisatellite Repeats; Molecular Epidemiology; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Serologic Tests; Tuberculosis Vaccines; Tuberculosis, Pulmonary	2007
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary	2008
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infection and immunity, 2008, Volume: 76, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Granuloma; Guinea Pigs; Humans; Hypoxia; Immunohistochemistry; Lung; Macaca fascicularis; Metronidazole; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nitroimidazoles; Oxygen; Rabbits; Radiation-Sensitizing Agents; Tuberculosis, Pulmonary	2008
In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:2 Topics: Animals; Antitubercular Agents; Bacteroides fragilis; Culture Media; Drug Resistance, Microbial; Female; Hydrogen-Ion Concentration; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Pulmonary	1993